BusinessMinerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive DisorderBy Nasdaq OMXApr 9, 2018, 12:30 PM UTC
BusinessMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive DisorderBy Nasdaq OMXDec 21, 2017, 1:00 PM UTC
BusinessMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive DisorderBy Nasdaq OMXSep 5, 2017, 12:00 PM UTC
BusinessNeuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive DisorderBy Nasdaq OMXFeb 16, 2017, 12:02 PM UTC
BusinessNeuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD.By Nasdaq OMXDec 12, 2016, 12:38 PM UTC
BusinessMinerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202By Nasdaq OMXMar 11, 2016, 1:30 PM UTC
